Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
The Role of the Vasculature in Immunotherapy
share announcement

The Role of the Vasculature in Immunotherapy

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (31 January 2021) | Viewed by 8952

Special Issue Editor

Prof. Dr. Jennifer R. Gamble

E-Mail Website
Guest Editor
Vascular Biology Program, Centenary Institute, The University of Sydney, Sydney 2050, Australia
Interests: endothelial cells; senescence; microRNA; vascular normalisation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The vasculature of solid cancers is both structurally and functionally abnormal. These abnormalities contribute to the hypoxic microenvironment, changes in the extracellular matrix, and to the immune cell composition within the tumour. Immunotherapy is improving our ability to treat many cancers. However, the underlying necessity of successful immunotherapy is the infiltration of appropriate immune subsets into the tumour. This Special Edition will focus on improving our understanding of the vascular control of immune cell infiltration into tumours.

Key areas (but not limited to these):

Immune–vascular cross-talk

Structure and function of tumour-associated vessels/implication for immune infiltration

Novel vascular therapeutic targets

Vascular control of leucocyte subsets

Circulating biomarkers to monitor changes in the vasculature

How can we improve normalisation in hard-to-treat tumours?

Vascular mimicry

Prof. Jennifer Gamble
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • normalization
  • vasculature
  • immunotherapy
  • immune subsets
  • endothelial cells
  • pericytes

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

26 pages, 1581 KiB  
Review
The Tumour Vasculature as a Target to Modulate Leucocyte Trafficking
by Yang Zhao, Ka Ka Ting, Paul Coleman, Yanfei Qi, Jinbiao Chen, Mathew Vadas and Jennifer Gamble
Cancers 2021, 13(7), 1724; https://doi.org/10.3390/cancers13071724 - 6 Apr 2021
Cited by 16 | Viewed by 4013
Abstract
The effectiveness of immunotherapy against solid tumours is dependent on the appropriate leucocyte subsets trafficking and accumulating in the tumour microenvironment (TME) with recruitment occurring at the endothelium. Such recruitment involves interactions between the leucocytes and the endothelial cells (ECs) of the vessel [...] Read more.
The effectiveness of immunotherapy against solid tumours is dependent on the appropriate leucocyte subsets trafficking and accumulating in the tumour microenvironment (TME) with recruitment occurring at the endothelium. Such recruitment involves interactions between the leucocytes and the endothelial cells (ECs) of the vessel and occurs through a series of steps including leucocyte capture, their rolling, adhesion, and intraluminal crawling, and finally leucocyte transendothelial migration across the endothelium. The tumour vasculature can curb the trafficking of leucocytes through influencing each step of the leucocyte recruitment process, ultimately producing an immunoresistant microenvironment. Modulation of the tumour vasculature by strategies such as vascular normalisation have proven to be efficient in facilitating leucocyte trafficking into tumours and enhancing immunotherapy. In this review, we discuss the underlying mechanisms of abnormal tumour vasculature and its impact on leucocyte trafficking, and potential strategies for overcoming the tumour vascular abnormalities to boost immunotherapy via increasing leucocyte recruitment. Full article
(This article belongs to the Special Issue The Role of the Vasculature in Immunotherapy)
►▼ Show Figures

Graphical abstract

14 pages, 1167 KiB  
Review
Modulation of the Vascular-Immune Environment in Metastatic Cancer
by Bo He and Ruth Ganss
Cancers 2021, 13(4), 810; https://doi.org/10.3390/cancers13040810 - 15 Feb 2021
Cited by 15 | Viewed by 4047
Abstract
Advanced metastatic cancer is rarely curable. While immunotherapy has changed the oncological landscape profoundly, cure in metastatic disease remains the exception. Tumor blood vessels are crucial regulators of tumor perfusion, immune cell influx and metastatic dissemination. Indeed, vascular hyperpermeability is a key feature [...] Read more.
Advanced metastatic cancer is rarely curable. While immunotherapy has changed the oncological landscape profoundly, cure in metastatic disease remains the exception. Tumor blood vessels are crucial regulators of tumor perfusion, immune cell influx and metastatic dissemination. Indeed, vascular hyperpermeability is a key feature of primary tumors, the pre-metastatic niche in host tissue and overt metastases at secondary sites. Combining anti-angiogenesis and immune therapies may therefore unlock synergistic effects by inducing a stabilized vascular network permissive for effector T cell trafficking and function. However, anti-angiogenesis therapies, as currently applied, are hampered by intrinsic or adaptive resistance mechanisms at primary and distant tumor sites. In particular, heterogeneous vascular and immune environments which can arise in metastatic lesions of the same individual pose significant challenges for currently approved drugs. Thus, more consideration needs to be given to tailoring new combinations of vascular and immunotherapies, including dosage and timing regimens to specific disease microenvironments. Full article
(This article belongs to the Special Issue The Role of the Vasculature in Immunotherapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop